Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus MEDROL ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus MEDROL ACETATE.
ASMANEX HFA vs MEDROL ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Methylprednisolone acetate is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators including prostaglandins, leukotrienes, and cytokines.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
4 to 48 mg orally once daily or in divided doses (e.g., 4 mg every 6 hours) depending on condition, typically starting at 4-48 mg/day. Also intramuscular (IM) as methylprednisolone acetate: 40-120 mg every 1-4 weeks. Intra-articular or soft tissue: 4-40 mg per injection depending on joint size.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life of methylprednisolone (active form) is approximately 1.8–3.5 hours. The biological half-life (duration of HPA suppression) is longer: 18–36 hours. Clinical context: Short plasma half-life but prolonged tissue effects due to receptor binding.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Primarily renal (urinary) as inactive metabolites. Approximately 10-20% of the dose is excreted unchanged in urine. Biliary/fecal excretion accounts for <5% of the dose.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid